UY36285A - Compuestos que inhiben la proteína mcl-1 - Google Patents

Compuestos que inhiben la proteína mcl-1

Info

Publication number
UY36285A
UY36285A UY0001036285A UY36285A UY36285A UY 36285 A UY36285 A UY 36285A UY 0001036285 A UY0001036285 A UY 0001036285A UY 36285 A UY36285 A UY 36285A UY 36285 A UY36285 A UY 36285A
Authority
UY
Uruguay
Prior art keywords
compounds
mcl
protein
inhibit
methods
Prior art date
Application number
UY0001036285A
Other languages
English (en)
Inventor
Brian S Lucas
Sean P Brown
Gonzalez Buenrostro Ana
Li Yunxiao
Lizarzaburu Mike Elias
Nick A Paras
Taygerly Joshua
Vimolratana Marc
Wang Xianghong
Yu Ming
Zancanella Manuel
Zhu Liusheng
Li Zhihong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY36285A publication Critical patent/UY36285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Abstract

Se proporcionan en la presente inhibidores de la proteína de leucemia de células mieloides 1 (Mcl-1), métodos de su preparación, composiciones farmacéuticas relacionadas,y métodos de uso de los mismos. Por ejemplo, se proporcionan en la presente compuestos de la Fórmula I,y sales farmacéuticamente aceptables de los mismos y composiciones farmacéuticas que contienen los compuestos. Los compuestos y composiciones proporcionadas en la presente se pueden usar, por ejemplo, en el tratamiento de enfermedades o afecciones, tal como cáncer.
UY0001036285A 2014-08-29 2015-08-31 Compuestos que inhiben la proteína mcl-1 UY36285A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462043929P 2014-08-29 2014-08-29

Publications (1)

Publication Number Publication Date
UY36285A true UY36285A (es) 2016-04-01

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036285A UY36285A (es) 2014-08-29 2015-08-31 Compuestos que inhiben la proteína mcl-1

Country Status (40)

Country Link
US (7) US9562061B2 (es)
EP (2) EP3424931B1 (es)
JP (1) JP6502479B2 (es)
KR (1) KR102466351B1 (es)
CN (1) CN107001387B (es)
AP (1) AP2017009827A0 (es)
AR (1) AR101729A1 (es)
AU (1) AU2015308735B2 (es)
BR (1) BR112017004209B1 (es)
CA (1) CA2959615C (es)
CL (1) CL2017000469A1 (es)
CO (1) CO2017002998A2 (es)
CR (1) CR20170116A (es)
CY (1) CY1121195T1 (es)
DK (1) DK3186259T3 (es)
EA (1) EA031223B1 (es)
ES (2) ES2777478T3 (es)
HR (1) HRP20190053T1 (es)
HU (1) HUE041806T2 (es)
IL (2) IL250843B (es)
JO (1) JO3474B1 (es)
LT (1) LT3186259T (es)
MA (1) MA40111B1 (es)
ME (1) ME03313B (es)
MX (1) MX2017002656A (es)
MY (1) MY176235A (es)
PE (1) PE20170892A1 (es)
PH (1) PH12017500367A1 (es)
PL (1) PL3186259T3 (es)
PT (1) PT3186259T (es)
RS (1) RS58276B1 (es)
SG (1) SG11201701525WA (es)
SI (1) SI3186259T1 (es)
TN (1) TN2017000067A1 (es)
TR (1) TR201901312T4 (es)
TW (1) TWI676628B (es)
UA (1) UA118233C2 (es)
UY (1) UY36285A (es)
WO (1) WO2016033486A1 (es)
ZA (2) ZA201701763B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
UY37843A (es) * 2017-08-15 2019-03-29 Abbvie Inc Inhibidores de mcl-1 macrocíclicos y métodos de uso
WO2019035927A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
US11364248B2 (en) 2017-08-18 2022-06-21 Amgen Inc. Compounds that inhibit Mcl-1 protein
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
US11274105B2 (en) 2018-03-05 2022-03-15 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
BR112020021648A2 (pt) 2018-05-14 2021-01-26 Gilead Sciences, Inc. inibidores de mcl-1
CN113166173A (zh) 2018-11-09 2021-07-23 普莱鲁德疗法有限公司 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
CN112867722B (zh) * 2019-01-18 2022-09-23 苏州亚盛药业有限公司 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers)
WO2020236825A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
KR20220024694A (ko) * 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CA3144558A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
EP3771469A1 (en) * 2019-07-30 2021-02-03 Amgen, Inc Formulations and dosages for administering a compound that inhibits mcl1 protein
CN112479876B (zh) * 2019-09-12 2023-07-21 苏州亚盛药业有限公司 氧氮杂环庚烷类螺环化合物、中间体及其制备方法
AU2020365113A1 (en) 2019-10-18 2022-04-07 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220105661A (ko) * 2019-11-26 2022-07-27 길리애드 사이언시즈, 인코포레이티드 Mcl1 억제제를 제조하기 위한 방법 및 중간체
CA3165735A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
JP2023514364A (ja) * 2020-02-21 2023-04-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状インドール誘導体
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
US20230039553A1 (en) 2020-05-01 2023-02-09 Gilead Sciences, Inc. Cd73 compounds
WO2021225823A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinylic protected alcohol intermediates
TW202208342A (zh) * 2020-05-06 2022-03-01 美商安進公司 乙烯基環丁基中間體之合成
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
CN115461332A (zh) * 2020-05-06 2022-12-09 安进公司 乙烯醇中间体的合成
EP4146622A1 (en) 2020-05-06 2023-03-15 Amgen Inc. Synthesis of sulfonamide intermediates
JP2023528965A (ja) * 2020-06-10 2023-07-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状２－アミノ－３－フルオロ－ブタ－３－エナミド
KR20230058694A (ko) 2020-09-03 2023-05-03 암젠 인크 친핵성 방향족 치환에 의한 디올 탈대칭화
EP4247783A1 (en) * 2020-11-19 2023-09-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN116745258A (zh) 2020-11-25 2023-09-12 安进公司 醛的对映选择性烯基化
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
EP4255409A1 (en) 2020-12-07 2023-10-11 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
KR20230121806A (ko) 2020-12-17 2023-08-21 얀센 파마슈티카 엔.브이. Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024516641A (ja) 2021-04-26 2024-04-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023088894A1 (en) 2021-11-16 2023-05-25 Janssen Pharmaceutica Nv Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230312602A1 (en) 2022-04-05 2023-10-05 Amgen Inc. Salt forms and solvates of mci-1 antagonists
WO2023196361A1 (en) 2022-04-05 2023-10-12 Amgen Inc. Amorphous and crystalline forms of mci-1 antagonists
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
EP1904047B1 (en) * 2005-07-07 2013-01-02 Abbott Laboratories Apoptosis promoters
EP2134684B1 (en) 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
DK2185562T3 (en) * 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
WO2011022312A1 (en) * 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
WO2011044375A2 (en) * 2009-10-08 2011-04-14 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
US20130035304A1 (en) 2010-01-29 2013-02-07 Walensky Loren D Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2013052943A2 (en) 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Small molecule inhibitors of mcl-1 and uses thereof
EP2831067B1 (en) 2012-03-29 2017-11-01 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein

Also Published As

Publication number Publication date
IL250843A0 (en) 2017-04-30
US11001598B2 (en) 2021-05-11
CA2959615C (en) 2023-01-17
LT3186259T (lt) 2019-02-25
TWI676628B (zh) 2019-11-11
US20210040120A1 (en) 2021-02-11
UA118233C2 (uk) 2018-12-10
US20230271981A1 (en) 2023-08-31
IL250843B (en) 2018-03-29
MX2017002656A (es) 2017-10-12
HRP20190053T1 (hr) 2019-02-22
CA2959615A1 (en) 2016-03-03
HUE041806T2 (hu) 2019-05-28
RS58276B1 (sr) 2019-03-29
IL257942B (en) 2020-05-31
PH12017500367B1 (en) 2017-07-10
EP3424931B1 (en) 2020-02-12
CN107001387A (zh) 2017-08-01
US10100063B2 (en) 2018-10-16
EP3186259B1 (en) 2018-12-19
EA201790492A1 (ru) 2017-07-31
KR20170043661A (ko) 2017-04-21
DK3186259T3 (en) 2019-02-25
US20200062780A1 (en) 2020-02-27
ZA201802865B (en) 2022-05-25
US10836779B2 (en) 2020-11-17
US20170088560A1 (en) 2017-03-30
CY1121195T1 (el) 2020-05-29
AU2015308735B2 (en) 2019-03-14
AU2015308735A1 (en) 2017-03-23
ES2777478T3 (es) 2020-08-05
EP3186259A1 (en) 2017-07-05
CO2017002998A2 (es) 2017-07-19
US9562061B2 (en) 2017-02-07
NZ729768A (en) 2021-06-25
IL257942A (en) 2018-05-31
US20190016736A1 (en) 2019-01-17
ME03313B (me) 2019-10-20
US20160068545A1 (en) 2016-03-10
SG11201701525WA (en) 2017-03-30
MA40111B1 (fr) 2018-12-31
MY176235A (en) 2020-07-24
KR102466351B1 (ko) 2022-11-10
US10494381B2 (en) 2019-12-03
TN2017000067A1 (en) 2018-07-04
MA40111A1 (fr) 2018-06-29
ES2706309T3 (es) 2019-03-28
PL3186259T3 (pl) 2019-04-30
CL2017000469A1 (es) 2017-11-03
JO3474B1 (ar) 2020-07-05
AP2017009827A0 (en) 2017-03-31
TW201625645A (zh) 2016-07-16
CR20170116A (es) 2017-04-28
US11685747B2 (en) 2023-06-27
EP3424931A3 (en) 2019-02-20
PH12017500367A1 (en) 2017-07-10
BR112017004209A2 (pt) 2018-07-31
PT3186259T (pt) 2019-02-06
WO2016033486A1 (en) 2016-03-03
AR101729A1 (es) 2017-01-11
US20190023720A1 (en) 2019-01-24
BR112017004209B1 (pt) 2022-08-09
TR201901312T4 (tr) 2019-02-21
EP3424931A2 (en) 2019-01-09
JP6502479B2 (ja) 2019-04-17
SI3186259T1 (sl) 2019-03-29
EA031223B1 (ru) 2018-12-28
ZA201701763B (en) 2018-08-29
CN107001387B (zh) 2019-03-05
PE20170892A1 (es) 2017-07-12
JP2017525730A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CR20150633A (es) Derivados del bipirazol como inhibidores jak
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
NI201500096A (es) Compuesto químicos
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
CL2017002229A1 (es) Inhibidores de bace1.
ECSP18056196A (es) Derivados de indano
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
CR20150584A (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230919